ETFs PharmaEssentia Corporation

6446

TW0006446008

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. 2026-09-29			5-day change	1st Jan Change
1,195.00 ^TWD	+3.46%		+3.02%	+182.04%

09-18	PharmaEssentia Gets Experts Board's Recommendation to Continue Phase 3 Myelofibrosis Drug Trial	MT
09-02	PharmaEssentia Receives FDA Approval For Ropeginterferon Alfa-2b-njft For Essential Thrombocythemia	CI

ETFs positioned on PharmaEssentia Corporation

Name	YTD change	Weight	AuM
STATE STREET SPDR S&P EMERGING MARKETS CARBON AWARE ETF - AUD	-0.85%	-.--%	21 M€
CI GROWTH ASSET ALLOCATION ETF -CAD	+10.54%	-.--%	67 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+6.19%	-.--%	37 M€
HSBC MSCI AC FAR EAST EX JAPAN UCITS ETF - USD	+34.95%	-.--%	457 M€
STATE STREET SPDR MSCI EM ASIA UCITS ETF - USD	+31.98%	-.--%	1,587 M€
ISHARES MSCI TAIWAN ETF - USD	+78.39%	0.54%	11,413 M€
XTRACKERS MSCI TAIWAN UCITS ETF 1C - USD	+77.54%	0.52%	421 M€
XTRACKERS MSCI TAIWAN UCITS ETF 1D - USD	+83.95%	0.5%	86 M€
FRANKLIN FTSE TAIWAN ETF - USD	+80.16%	0.46%	3,436 M€
ISHARES AGEING POPULATION UCITS ETF - USD	+9.88%	0.43%	937 M€
FRANKLIN FTSE TAIWAN UCITS ETF - USD	-.--%	0.35%	884 M€
ISHARES MSCI TAIWAN UCITS ETF - USD	+82.17%	0.35%	1,565 M€
HSBC MSCI TAIWAN CAPPED UCITS ETF - USD	+78.33%	0.34%	110 M€
HSBC MSCI EMERGING MARKETS VALUE ESG UCITS ETF - USD	+22.44%	0.33%	122 M€
UBS MSCI EM EX CHINA SOCIALLY RESPONSIBLE UCITS ETF - USD	+54.94%	0.31%	18 M€
AMUNDI MSCI EMERGING EX CHINA ESG SELECTION - UCITS ETF DR (C) - USD	+24.37%	0.18%	1,000 M€
XTRACKERS MSCI EMERGING MARKETS ESG UCITS ETF 1C - USD	+9.29%	0.16%	1,545 M€
UBS MSCI AC ASIA EX JAPAN SELECTION UCITS ETF A-ACC - USD	+27.11%	0.16%	10 M€
INVESCO MSCI EMERGING MARKETS UNIVERSAL SCREENED UCITS ETF ACC - USD	+32.16%	0.16%	169 M€
ISHARES ESG MSCI EM LEADERS ETF DIST - USD	+4.78%	0.15%	33 M€
ISHARES ESG AWARE MSCI EM ETF - USD	+22.96%	0.12%	6,821 M€
XTRACKERS EMERGING MARKETS NET ZERO PATHWAY PARIS ALIGNED UCITS ETF 1C - USD	+33.90%	0.11%	17 M€
AMUNDI MSCI AC FAR EAST EX JAPAN ESG SELECTION - UCITS ETF - USD	+19.02%	0.11%	5 M€
AMUNDI MSCI EMERGING MARKETS ESG SELECTION - UCITS ETF DR (C) - USD	+15.33%	0.11%	1,125 M€
ISHARES ESG ADVANCED MSCI EM ETF - USD	+24.04%	0.11%	164 M€
FIRST TRUST EMERGING MARKETS HUMAN FLOURISHING ETF - USD	+49.19%	0.1%	122 M€
INVESCO MSCI EMERGING MARKETS ESG CLIMATE PARIS ALIGNED UCITS ETF ACC - USD	+22.24%	0.1%	155 M€
ISHARES MSCI GLOBAL MIN VOL FACTOR ETF - USD	+4.00%	0.1%	3,371 M€
ISHARES EDGE MSCI MIN VOL GLOBAL INDEX ETF (CAD-HEDGED) - CAD	+3.48%	0.1%	16 M€
WISDOMTREE EMERGING MARKETS EX-STATE-OWNED ENTERPRISES FUND - USD	+20.58%	0.09%	2,106 M€
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY ETF - USD	+22.63%	0.09%	1,699 M€
UBS MSCI EM EX CHINA UCITS ETF (USD) A-ACC - USD	+42.02%	0.09%	100 M€
DESJARDINS RI EMERGING MARKETS - NET-ZERO EMISSIONS PATHWAY ETF - CAD	+30.37%	0.09%	58 M€
FRANKLIN FTSE ASIA EX CHINA EX JAPAN UCITS ETF - USD	+42.69%	0.08%	592 M€
XTRACKERS MSCI EMERGING MARKETS EX CHINA UCITS ETF 1C - GBP	+37.72%	0.08%	168 M€
XTRACKERS MSCI EMERGING MARKETS CLIMATE TRANSITION UCITS ETF 1C - USD	+27.91%	0.07%	42 M€
FRANKLIN FTSE EMERGING EX CHINA UCITS ETF - USD	-.--%	0.07%	7 M€

1 2 3 4 5

PHARMAESSENTIA CORPORATION is a Taiwan-based company primarily engaged in the research and development, clinical trials, manufacturing, sale, and marketing of innovative biotechnology drugs. It also oversees registration and marketing authorization applications based on product development progress. The Company focuses on hematology and oncology, utilizing the PEGylation technology platform for drug candidate design and development. The Companyâ€™s proprietary product, Ropeg, is used to treat polycythemia vera (PV), primarily sold in the United States.

Employees

131

Sector

Biotechnology & Medical Research

More about the company